|
|
PEGylation and Biologic Therapy
Proteins as drug therapy
Advances in biotechnology have made it possible to engineer biologic therapies that harness the functional capabilities of many types of proteins,1 including enzymes, hormones, cytokines, and antibodies.2
Proteins by nature, however, are unstable molecules with fundamental properties that may limit their therapeutic utility.1 They are subject to destruction by proteolytic enzymes and rapid renal clearance, resulting in a short circulating half-life. They also are potentially immunogenic.3
PEGylation changes the physical and chemical properties of therapeutic proteins1
One method that has proven successful in overcoming the inherent limitations of proteins as drug therapy is to covalently join the protein with polyethylene glycol (PEG), a nontoxic, nonimmunogenic polymer approved by the US Food and Drug Administration for use in foods, cosmetics, and pharmaceuticals.3
Conjugation with PEG, termed PEGylation, modifies the structure and function of the parent protein, resulting in a compound with improved therapeutic capabilities.1 In recent decades, the development of PEGylated protein therapies has led to important advances in the treatment of several disorders, including severe combined immunodeficiency disease (SCID), leukemia, chemotherapy-induced neutropenia, hepatitis C, and acromegaly.2
PEGylated drug therapies have been in clinical practice since 19901
Click to enlarge
Unique properties of PEGylated proteins
PEG has several beneficial properties that transfer to compounds to which it is covalently bound.1,2 PEG is highly water soluble as well as flexible and stable in solution.1,2 It also tightly binds to water molecules, resulting in increased hydrodynamic volume.1,2
As a result of PEGylation, a therapeutic protein becomes highly hydrated and mobile in solution and much larger than the parent protein,3 with the following advantages:
- Prolonged circulation time due to protection against enzymatic degradation and slower renal filtration (decreased drug clearance)2
- Improved stability over a range of pH and temperature changes3
Because PEGylation results in delayed elimination and therefore an extended drug half-life, it allows a reduced dosing frequency.1
CIMZIA is the only PEGylated anti-TNF
There has been increasing interest in the use of antibodies and antibody fragments as the basis for new therapies to combat chronic disease.4
An important example is the development of agents aimed at downregulating the function of TNF-alpha. TNF-alpha is a key cytokine involved in mediating the chronic pathologic inflammation that contributes to joint destruction in rheumatoid arthritis.5
CIMZIA is the only PEGylated anti-TNF therapy. CIMZIA is composed of the Fab' antigen-binding domain of a humanized anti-TNF antibody, site-specifically bound to PEG so that it does not interfere with TNF binding.1,5 In studies, CIMZIA was shown to bind to and neutralize both membrane-bound and soluble human TNF-alpha in a dose-dependent manner.5
CIMZIA is the only PEGylated anti-TNF5
Click to enlarge
Because it lacks the Fc portion of the antibody, CIMZIA does not fix complement or induce antibody-dependent cell-mediated cytotoxicity in vitro.5 The clinical relevance of in vitro findings is unknown. CIMZIA also does not induce apoptosis or neutrophil degranulation.5
CIMZIA is administered by subcutaneous injection and is designed so it can be dosed on an every 4 weeks basis.5
Watch a video about the mechanism of action of CIMZIA
References:
1. Veronese FM, Mero A. The impact of PEGylation on biological therapies. Biodrugs. 2008;22:315-329.
2. Fishburn SC. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
J Pharm Sci. 2008;97:4167-4183.
3. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2:214-221.
4. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review.
Adv Drug Deliv Rev. 2002;54:531-545.
5. CIMZIA [prescribing information]. Smyrna, GA: UCB, Inc.; 2009.
|
|
Your patients may be
eligible to save up to
$500 per pack on
CIMZIA prescriptions
|
 |
